welcome to oneEDSvoice
- a positively charged Ehlers Danlos Syndrome community.- join today!
- login
Acer jumps on 7-year-old data
Acer Therapeutics Inc. had a welcoming first week on the Nasdaq stock exchange, seeing shares sruge more 10% Monday after verifying positive clinical results published almost seven years ago from a study of celiprolol, the active ingredient in its lead drug candidate.
The study tested celiprolol against placebo in patients with vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening disorder that causes arteries and organs to easily rupture. After receiving treatment for about four years on average, 20% of the participants in the investigational arm experienced arterial events versus 50% of those in the control arm.
expertly curated content related to this topic
-
Headaches and Hypermobilityhttps://www.oneedsvoice.com/wp-content/u...
-
You know you have EDS when…Welcome to the world of bizarre things t...
-
Genetic Disorders of CollagenThe term 'collagen disease' should be co...
-
If You Can’t Connect the Issues, Think Connective Tissues (Heidi Collins, MD)https://www.youtube.com/watch?v=H0jaF6Rn...
-
When Flexibility is not Necessarily a Virtue: A Review of Hypermobility Syndromes and Chronic or Recurrent Musculosk...Chronic or recurrent musculoskeletal pai...
-
Ehlers Danlos Syndrome (Ash)Information on Ehlers-Danlos Syndrome...
-
Ehlers-Danlos SyndromeFor the final post in my blog I thought ...
